CA3119329A1 - Characterizing methylated dna, rna, and proteins in the detection of lung neoplasia - Google Patents

Characterizing methylated dna, rna, and proteins in the detection of lung neoplasia Download PDF

Info

Publication number
CA3119329A1
CA3119329A1 CA3119329A CA3119329A CA3119329A1 CA 3119329 A1 CA3119329 A1 CA 3119329A1 CA 3119329 A CA3119329 A CA 3119329A CA 3119329 A CA3119329 A CA 3119329A CA 3119329 A1 CA3119329 A1 CA 3119329A1
Authority
CA
Canada
Prior art keywords
methylation
marker
dna
max
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3119329A
Other languages
English (en)
French (fr)
Inventor
Hatim Allawi
Graham P. Lidgard
Maria GIAKOUMOPOULOS
David A. Ahlquist
William R. Taylor
Douglas Mahoney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exact Sciences Corp
Mayo Clinic in Florida
Original Assignee
Exact Sciences Development Co LLC
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exact Sciences Development Co LLC, Mayo Clinic in Florida filed Critical Exact Sciences Development Co LLC
Publication of CA3119329A1 publication Critical patent/CA3119329A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3119329A 2018-11-27 2019-11-26 Characterizing methylated dna, rna, and proteins in the detection of lung neoplasia Pending CA3119329A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862771965P 2018-11-27 2018-11-27
US62/771,965 2018-11-27
PCT/US2019/063401 WO2020112869A1 (en) 2018-11-27 2019-11-26 Characterizing methylated dna, rna, and proteins in the detection of lung neoplasia

Publications (1)

Publication Number Publication Date
CA3119329A1 true CA3119329A1 (en) 2020-06-04

Family

ID=70853661

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3119329A Pending CA3119329A1 (en) 2018-11-27 2019-11-26 Characterizing methylated dna, rna, and proteins in the detection of lung neoplasia

Country Status (10)

Country Link
US (1) US20220136058A1 (enExample)
EP (1) EP3886878A4 (enExample)
JP (2) JP7512278B2 (enExample)
KR (1) KR20210099044A (enExample)
CN (1) CN113423410A (enExample)
AU (1) AU2019389008A1 (enExample)
BR (1) BR112021009795A2 (enExample)
CA (1) CA3119329A1 (enExample)
MX (1) MX2021005963A (enExample)
WO (1) WO2020112869A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2255198A4 (en) 2008-02-15 2011-05-25 Mayo Foundation DETECTION OF NEOPLASM
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US11078539B2 (en) 2014-03-31 2021-08-03 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasm
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
EP3274440A4 (en) 2015-03-27 2019-03-06 Exact Sciences Corporation Detecting esophageal disorders
CA3233310A1 (en) 2015-10-30 2017-05-04 Exact Sciences Development Company, Llc Multiplex amplification detection assay and isolation and detection of dna from plasma
KR102436270B1 (ko) 2016-05-05 2022-08-25 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 메틸화된 dna 분석에 의한 폐 종양의 검출
CA3049459A1 (en) 2017-01-27 2018-08-02 Exact Sciences Development Company, Llc Detection of colon neoplasia by analysis of methylated dna
CN111655869B (zh) 2017-11-30 2024-06-28 梅约医学教育与研究基金会 检测乳腺癌
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
EP4022093A4 (en) * 2019-08-27 2024-05-22 Exact Sciences Corporation CHARACTERIZATION OF METHYLATED DNA, RNA AND PROTEINS IN SUBJECTS SUSPECTED TO HAVE LUNG NEOPLASIA
US20230046033A1 (en) 2019-09-16 2023-02-16 Exact Sciences Corporation Structure and temperature-dependent flap endonuclease substrates
CA3154354A1 (en) 2019-10-31 2021-05-06 William R. Taylor Detecting ovarian cancer
US11898199B2 (en) 2019-11-11 2024-02-13 Universal Diagnostics, S.A. Detection of colorectal cancer and/or advanced adenomas
WO2021228418A1 (en) 2020-05-15 2021-11-18 Universal Diagnostics, S.L. Methods and systems for identifying methylation biomarkers
WO2022002424A1 (en) 2020-06-30 2022-01-06 Universal Diagnostics, S.L. Systems and methods for detection of multiple cancer types
EP3945135A1 (en) * 2020-07-27 2022-02-02 Les Laboratoires Servier Biomarkers for diagnosing and monitoring lung cancer
US20220243278A1 (en) * 2021-01-29 2022-08-04 Mayo Foundation For Medical Education And Research Detecting the presence or absence of multiple types of cancer
CN115505640A (zh) * 2021-06-22 2022-12-23 上海鹍远生物科技股份有限公司 检测肺癌的dna甲基化标志物及应用
CN115725734B (zh) * 2022-08-10 2023-10-13 人和未来生物科技（长沙）有限公司 Znf781基因在制备宫颈癌诊断试剂中的应用
CN117683877A (zh) * 2023-12-19 2024-03-12 上海交通大学医学院 一种诊断或治疗免疫系统疾病的生物标志物或靶点

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264659A1 (en) * 2006-05-11 2007-11-15 Sungwhan An Lung cancer biomarker discovery
JPWO2010064702A1 (ja) 2008-12-05 2012-05-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー
WO2010074924A1 (en) * 2008-12-23 2010-07-01 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
WO2013055530A1 (en) * 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013070950A1 (en) * 2011-11-08 2013-05-16 University Of Southern California Identification of a dna methylation marker for blood-based detection of ovarian cancer
US9546403B1 (en) * 2011-12-14 2017-01-17 University Of Utah Research Foundation Substrate for methylated DNA testing
ES2879964T3 (es) * 2014-12-12 2021-11-23 Exact Sciences Dev Co Llc Composiciones y métodos para realizar ensayos de detección de metilación
JP6877704B2 (ja) * 2015-11-16 2021-05-26 公立大学法人名古屋市立大学 膵臓癌の検出のための方法及びキット
KR102436270B1 (ko) * 2016-05-05 2022-08-25 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 메틸화된 dna 분석에 의한 폐 종양의 검출
SG11201810914VA (en) * 2016-06-21 2019-01-30 Wistar Inst Compositions and methods for diagnosing lung cancers using gene expression profiles
US11345949B2 (en) * 2016-07-19 2022-05-31 Exact Sciences Corporation Methylated control DNA

Also Published As

Publication number Publication date
JP2022513658A (ja) 2022-02-09
AU2019389008A1 (en) 2021-06-03
MX2021005963A (es) 2021-08-24
JP7512278B2 (ja) 2024-07-08
EP3886878A1 (en) 2021-10-06
EP3886878A4 (en) 2022-11-02
WO2020112869A1 (en) 2020-06-04
US20220136058A1 (en) 2022-05-05
CN113423410A (zh) 2021-09-21
JP2024123233A (ja) 2024-09-10
BR112021009795A2 (pt) 2021-08-17
KR20210099044A (ko) 2021-08-11

Similar Documents

Publication Publication Date Title
US11028447B2 (en) Detection of neoplasia by analysis of methylated dna
JP7512278B2 (ja) 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定
JP7670662B2 (ja) メチル化ｄｎａの分析による腫瘍の検出
US20220403471A1 (en) Characterizing methylated dna, rna, and proteins in subjects suspected of having lung neoplasia
EP3488004B1 (en) Methylated control dna
HK40073060B (en) Methylated control dna
HK40073060A (en) Methylated control dna
KR20250171455A (ko) 메틸화된 dna 분석에 의한 결장 신조직형성의 검출

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920